comparemela.com

Latest Breaking News On - Andres ruiz briseno - Page 2 : comparemela.com

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(4) - April 26, 2024

SOUTH SAN FRANCISCO, Calif. - IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25,.

Andres ruiz brisenoBiosciences incCompensation committeeInducement incentive award planNasdaq listing ruleNasdaq global select marketVice presidentNews publishing

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 26, 2024 /PRNewswire/ IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics,.

Andres ruiz brisenoBiosciences incCompensation committeeInducement incentive award planNasdaq listing ruleNasdaq global select marketVice president

IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study

/PRNewswire/ IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted.

United statesAnthony joshuaAndres ruiz brisenoExchange commissionAmerican society of clinical oncologyBiosciences incClinical oncologyAnnual meetingEfficacy studyAdjuvant darovasertibLocalized ocularInvestor relations

IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer

Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on AE profile and preliminary clinical efficacy observed, including multiple partial.

Andres ruiz brisenoMichael whiteDarrin beaupreExchange commissionBiosciences incChief medical officerChief scientific officerInvestor relations

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., April 5, 2024 /PRNewswire/ IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today.

Andres ruiz brisenoCompensation committeeBiosciences incInducement incentive award planNasdaq listing ruleNasdaq global select marketVice president

vimarsana © 2020. All Rights Reserved.